Acute myeloid leukemia: open trials in Denmark

• 2026-525234-39-00

  A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

  Trial Treatment · Phase 1 · Janssen Cilag International

  Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-11-06

• NCT07223814

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland

  Aalborg University Hospital, Aalborg · Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-11-06

• NCT06788509

  A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

  Trial Treatment · Phase 1 · Janssen Research & Development, LLC

  Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-11-04

• NCT07384715

  First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

  Trial Treatment · Phase 1 · Genmab

  Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe

  Registry updated 2026-11-04

• NCT06852222

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  Trial Treatment · Phase 3 · Janssen Research & Development, LLC

  Aalborg University Hospital, Aalborg · Rigshospitalet, Copenhagen · Zealand University Hospital, Køge · Odense University Hospital, Odense

  Registry updated 2026-11-03

• NCT07155226

  Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  Trial Treatment · Phase 1/2 · AstraZeneca

  Rigshospitalet, Copenhagen Oe

  Registry updated 2026-10-23

• 2024-512753-24-00

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  Trial Treatment · Phase 3 · Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

  Aalborg University Hospital, Aalborg · Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C · Region Sjaelland, Roskilde

  Registry updated 2026-10-21

• 2023-506546-23-00

  Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study)

  Trial Treatment · Phase 3 · Prinses Maxima Centrum voor Kinderoncologie B.V.

  Aarhus Universitetshospital, Aarhus N · Rigshospitalet, Copenhagen Oe

  Registry updated 2026-10-16

• 2023-504999-25-00

  CHIP-AML22 Master protocol: Protocol for the treatment of children and adolescents with Acute Myeloid Leukemia (AML)

  Trial Treatment · Phase 3 · Prinses Maxima Centrum voor Kinderoncologie B.V.

  Aarhus Universitetshospital, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-09-23

• NCT06652438

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland

  Aalborg University Hospital, Aalborg · Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2026-09-02

• NCT05444348

  Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

  Trial Treatment · Christoffer Johansen

  Aalborg Universitetshospital, Aalborg · Aarhus Universitetshospital, Aarhus · Sydvestjysk sygehus - Esbjerg, Esbjerg · Regionshospitalet Gødstrup, Herning · Odense Universitetshospital, Odense · Sjællands Universitetshospital_Roskilde, Roskilde · Lillebælt syge - Vejle Sygehus, Vejle

  Registry updated 2026-08-12

• 2025-521390-14-00

  Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)

  Trial Treatment · Phase 2 · Pediatric Research International GmbH

  Aarhus Universitetshospital, Århus · Copenhagen University Hospital, Copenhagen Oe

  Registry updated 2026-08-04

• 2024-516116-19-00

  VICTOR: Venetoclax or Intensive Chemotherapy for Treatment Of Favourable Risk Acute Myeloid Leukaemia: a molecularly guided phase 2 study

  Trial Treatment · Phase 2 · The University Of Birmingham

  Aarhus Universitetshospital, Aarhus N

  Registry updated 2026-04-09

• NCT07075016

  Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

  Trial Treatment · Phase 3 · Stichting Hemato-Oncologie voor Volwassenen Nederland

  DK-Aalborg-AALBORGUH, Aalborg · DK-Aarhus N-AUH, Aarhus N · DK-Copenhagen-RIGSHOSPITALET, Copenhagen · DK-Odense-OUH, Odense · DK-Roskilde-ROSKILDE, Roskilde

  Registry updated 2025-08-19

• NCT06262438

  CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

  Trial Treatment · Phase 2 · Princess Maxima Center for Pediatric Oncology

  Aarhus University Hospital, Aarhus N · Rigshospitalet, Copenhagen Oe

  Registry updated 2025-08-05

• NCT05477589

  Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

  Trial Treatment · Phase 3 · Vastra Gotaland Region

  Paediatric Stem Cell Transplant and Immune Deficiency, Department of Pediatric and Adolescent Medicine, Section 4072, Rigshospitalet University Hospital of Copenhagen, Copenhagen

  Registry updated 2024-12-19

• NCT01828489

  NOPHO-DBH AML 2012 Protocol: Research study for treatment of children and adolescents with acute myeloid leukemia 0-18 years

  Trial Treatment · Phase 3 · Vaestra Goetalandsregionen

  Region Midtjylland, Aarhus N · Rigshospitalet, Copenhagen Oe

  Registry updated 2024-11-22

• NCT03999723

  Combining Active and Passive DNA Hypomethylation

  Trial Treatment · Phase 2 · Kirsten Grønbæk

  Aalborg University Hospital, Aalborg · Aarhus University Hospital, Aarhus · Herlev University Hospital, Copenhagen · Rigshospitalet, Copenhagen · Odense University Hospital, Odense · Zealand University Hospital, Roskilde

  Registry updated 2024-04-17

• NCT04793919

  Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

  Trial Treatment · Phase 2 · Associazione Italiana Ematologia Oncologia Pediatrica

  Pediatrics and Adolescent Medicine Aarhus University Hospital, Aarhus N

  Registry updated 2024-04-15

• NCT05431257

  Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling

  Trial Treatment · Phase 2 · Copenhagen University Hospital, Rigshospitalet

  Aalborg University Hospital, Aalborg · Aarhus Universitet, Aarhus N · Rigshospitalet, Copenhagen Oe · Odense University Hospital, Odense C

  Registry updated 2022-06-24

All Acute myeloid leukemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error